MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Simulations Plus Inc

Closed

SectorHealthcare

11.95 -0.17

Overview

Share price change

24h

Current

Min

11.93

Max

12.05

Key metrics

By Trading Economics

Income

1.4M

676K

Sales

961K

18M

Dividend yield

0.48

Profit margin

3.67

Employees

212

EBITDA

-3M

2.3M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+58.47% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.48%

2.45%

Next Earnings

9 kwi 2026

Market Stats

By TradingEconomics

Market Cap

-139M

229M

Previous open

12.12

Previous close

11.95

News Sentiment

By Acuity

58%

42%

293 / 349 Ranking in Healthcare

Simulations Plus Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 kwi 2026, 04:27 UTC

Major News Events

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 kwi 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2026, 18:30 UTC

Major News Events

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 kwi 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 kwi 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 kwi 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 kwi 2026, 16:50 UTC

Major News Events

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 kwi 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2026, 16:12 UTC

Earnings

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 kwi 2026, 15:56 UTC

Market Talk
Major News Events

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 kwi 2026, 15:56 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

3 kwi 2026, 15:56 UTC

Market Talk
Major News Events

Global Forex and Fixed Income Roundup: Market Talk

3 kwi 2026, 15:20 UTC

Major News Events

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 kwi 2026, 15:08 UTC

Acquisitions, Mergers, Takeovers

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 kwi 2026, 14:11 UTC

Market Talk
Major News Events

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 kwi 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 kwi 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3 kwi 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 kwi 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 kwi 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 kwi 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3 kwi 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 kwi 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3 kwi 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 kwi 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 kwi 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 kwi 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 kwi 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 kwi 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Peer Comparison

Price change

Simulations Plus Inc Forecast

Price Target

By TipRanks

58.47% upside

12 Months Forecast

Average 19 USD  58.47%

High 19 USD

Low 19 USD

Based on 4 Wall Street analysts offering 12 month price targets forSimulations Plus Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Sentiment

By Acuity

293 / 349 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat